This review article encompasses the historical perspective of androgen deprivation therapy by first reviewing the early research conducted by Huggins and Hodge, followed by a cellular biological discussion of androgen receptors in prostate cancer (PCa) physiology, leading to a subsequent discussion of the risk and potential therapeutic role of testosterone therapy in localized, oligometastatic, and metastatic PCa.
No takes yet. Share an insight, caveat, or question.
Johny et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: